• Upstream Bio outlined plans to meet FDA in mid-2026, with Phase 3 starts in severe asthma and CRSwNP targeted for Q1 2027.
• Pipeline centers on verekitug, a TSLP receptor antagonist, positioned for a single quarterly at-home injection using an autoinjector.
• Phase 2 severe asthma data: 56% AAER reduction vs placebo (p<0.0003), 122 mL FEV1 improvement, 20.4 ppb FeNO reduction, 0.21 ACQ-6 reduction.
• Phase 2 CRSwNP data: NPS reduction of -1.8 (p<0.0001), NCS reduction of -0.8 (p=0.0003), 76% lower surgery or steroid need (p=0.03).
• COPD Phase 2 VENTURE enrollment completed, with data expected in H2 2027; existing capital expected to fund operations through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.